CD19 and plasma cell myeloma: Moreover, while the three BAFF targets of TriBAFF/CD3/ABDCon are relevant in a wide spectrum of B-cell malignancies, including leukemia, lymphoma, and myeloma, pro-B cells do not express these receptors (Wong et al., 2022), which could mitigate the risk of B-cell aplasia commonly associated with CD19-targeted therapies.